MedPath

Sulfadiazine

Generic Name
Sulfadiazine
Drug Type
Small Molecule
Chemical Formula
C10H10N4O2S
CAS Number
68-35-9
Unique Ingredient Identifier
0N7609K889
Background

One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.

Indication

For the treatment of rheumatic fever and meningococcal meningitis

Associated Conditions
Acute Otitis Media caused by Haemophilus Influenzae, Chancroid, Conjunctivitis, Inclusion, Encephalitis, Malaria caused by Plasmodium falciparum, Meningitis caused by Haemophilus influenzae, Meningococcal Meningitis, Nocardiosis, Trachoma, Urinary Tract Infection, Wound Infections, Recurrent Rheumatic fever
Clinical Trials
Related News

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Phase 1
Active, not recruiting
Conditions
Myelodysplastic Syndromes
Interventions
Drug: ASTX727 LD
First Posted Date
2018-04-19
Last Posted Date
2025-05-04
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
160
Registration Number
NCT03502668
Locations
🇺🇸

Indiana University Health Hospital - Simon Cancer Center, Indianapolis, Indiana, United States

🇺🇸

The University of Chicago, Chicago, Illinois, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

and more 26 locations

Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Spray Dried BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-07-25
Last Posted Date
2014-07-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
63
Registration Number
NCT02199860

Study of GSK961081 in Healthy Volunteer Subjects

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: GSK961081 300mcg RD
Drug: GSK961081 100mcg RD
Drug: Placebo RD
First Posted Date
2009-04-24
Last Posted Date
2021-10-06
Lead Sponsor
Theravance Biopharma
Target Recruit Count
46
Registration Number
NCT00887406
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

Phase 2
Completed
Conditions
HIV Infections
Toxoplasmosis, Cerebral
First Posted Date
2001-08-31
Last Posted Date
2021-10-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
100
Registration Number
NCT00000794
Locations
🇺🇸

Northwestern University CRS, Chicago, Illinois, United States

🇺🇸

Cook County Hosp. CORE Ctr., Chicago, Illinois, United States

🇺🇸

Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

and more 13 locations

Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

Phase 4
Recruiting
Conditions
Toxoplasmosis
Interventions
First Posted Date
1999-10-19
Last Posted Date
2009-05-14
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
600
Registration Number
NCT00004317
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy